<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - INTRA-UTERINE CONTRACEPTIVE DEVICES (COPPER)</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>INTRA-UTERINE CONTRACEPTIVE DEVICES (COPPER)</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception</span>,
            </h4>
            <p class="specificity"><span class="route">By intra-uterine administration</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>If an intra-uterine device fails and the woman wishes to continue to full-term the device should be removed in the first trimester if possible.</p><p>Remove device; if pregnancy occurs, increased likelihood that it may be ectopic.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active trophoblastic disease (until return to normal of urine and plasma-gonadotrophin concentration)</li>
            <li>distorted uterine cavity</li>
            <li>established or marked immunosuppression</li>
            <li>genital malignancy</li>
            <li>medical diathermy</li>
            <li>pelvic inflammatory disease</li>
            <li>recent sexually transmitted infection (if not fully investigated and treated)</li>
            <li>severe anaemia</li>
            <li>small uterine cavity</li>
            <li>unexplained uterine bleeding</li>
            <li>Wilson&#8217;s disease</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Allergy, bleeding (on insertion), cervical perforation, displacement, dysmenorrhoea, expulsion, menorrhagia, occasionally epileptic seizure (on insertion), pain (on insertion, alleviated by NSAID such as ibuprofen 30 minutes before insertion), pelvic infection may be exacerbated, uterine perforation, vasovagal attack (on insertion),
              </p>
        
        
            <section class="advice">
                <h3>Presence of significant symptoms (especially pain)</h3>
              <p>Advise the patient to seek medical attention promptly in case of significant symptoms.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>The timing and technique of fitting an intra-uterine device are critical for its subsequent performance. <i>The healthcare professional inserting (or removing) the device should be fully trained in the technique and should provide full counselling backed, where available, by the patient information leaflet.</i> Devices should not be fitted during the heavy days of the period; they are best fitted after the end of menstruation and before the calculated time of implantation.</p>
            </section>
      </section>



      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>MHRA/CHM advice (June 2015) Intra-uterine contraception: uterine perforation&amp;#8212;updated information on risk factors</h3>
              <p>Uterine perforation most often occurs during insertion, but might not be detected until sometime later. The risk of uterine perforation is increased when the device is inserted up to 36 weeks postpartum or in patients who are breastfeeding. Before inserting an intra-uterine contraceptive device, inform patients that perforation occurs in approximately 1 in every 1000 insertions and signs and symptoms include:</p><ul>
            <li>severe pelvic pain after insertion (worse than period cramps);</li>
            <li>pain or increased bleeding after insertion which continues for more than a few weeks;</li>
            <li>sudden changes in periods;</li>
            <li>pain during intercourse;</li>
            <li>unable to feel the threads.</li>
            </ul><p>Patients should be informed on how to check their threads and to arrange a check-up if threads cannot be felt, especially if they also have significant pain. Partial perforation may occur even if the threads can be seen; consider this if there is severe pain following insertion and perform an ultrasound.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Anaemia
          </li>
          <li>
            anticoagulant therapy (avoid if possible)
          </li>
          <li>
            diabetes
          </li>
          <li>
            disease-induced immunosuppression (risk of infection&#8212;avoid if marked immunosuppression)
          </li>
          <li>
            drug-induced immunosuppression (risk of infection&#8212;avoid if marked immunosuppression)
          </li>
          <li>
            endometriosis
          </li>
          <li>
            epilepsy (risk of seizure at time of insertion)
          </li>
          <li>
            fertility problems
          </li>
          <li>
            history of pelvic inflammatory disease
          </li>
          <li>
            increased risk of expulsion if inserted before uterine involution
          </li>
          <li>
            menorrhagia (progestogen intra-uterine system might be preferable)
          </li>
          <li>
            nulliparity
          </li>
          <li>
            severe cervical stenosis
          </li>
          <li>
            severe primary dysmenorrhoea
          </li>
          <li>
            severely scarred uterus (including after endometrial resection)
          </li>
          <li>
            young age
          </li>
        </ul>
        <ul>
          <li>
            <p>The main excess risk of infection occurs in the first 20 days after insertion and is believed to be related to existing carriage of a sexually transmitted infection. Women are considered to be at a higher risk of sexually transmitted infections if:</p><ul>
        <li> they are under 25 years old <i>or</i>
        </li>
        <li>they are over 25 years old <i>and</i>
        </li>
        <li>
        <ul>
        <li>have a new partner <i>or</i>
        </li>
        <li>have had more than one partner in the past year <i>or</i>
        </li>
        <li>their regular partner has other partners.</li>
        </ul>
        </li>
        </ul><p>In these women, pre-insertion screening (for chlamydia and, depending on sexual history and local prevalence of disease, <ph outputclass="organism">
        <i>Neisseria gonorrhoeae</i>
        </ph>) should be performed. If results are unavailable at the time of fitting an intrauterine device for emergency contraception, appropriate prophylactic antibacterial cover should be given. The woman should be advised to attend <i>as an emergency</i> if she experiences sustained pain during the next 20 days.</p><p>An intra-uterine device should not be removed in mid-cycle unless an additional contraceptive was used for the previous 7 days. If removal is essential post-coital contraception should be considered.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Gynaecological examination before insertion, 6&#8211;8 weeks after insertion, then annually.</p>
            </section>
      </section>










      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contraindicated if patient has a copper allergy.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of INTRA-UTERINE CONTRACEPTIVE DEVICES (COPPER)</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP105341"><a href="../medicinalForm/PHP105341.html" data-target="#PHP105341" data-action="load">Products without form</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
